Seeking Alpha
What is your profession? ×
Profile| Send Message|
( followers)

If you are interested in healthcare stocks, but are uncertain as to where to begin your search, companies that have been recently rated as 'Strong Buy' by industry analysts is a good place to start. These companies have passed through several screens already. Today, we searched for stocks of this nature and then narrowed our focus to ones that are predicted for impressive growth in the near future. We think you will be intrigued by what we found.

EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. The 5-Year Expected EPS Growth Rate is a long-term annual growth estimate, where the growth projections are made by analysts, the company or other credible sources.

We first looked for healthcare stocks. From here, we looked for companies that are considered high-growth, with 5-year projected EPS growth of above 25%. We then looked for companies that analysts rate as "Strong Buy" (mean recommendation <2). We did not screen out any market caps.

Do you think these stocks are undervalued? Use this list as a starting-off point for your own analysis.

1) AtriCure, Inc. (NASDAQ:ATRC)

Industry:Medical Instruments & Supplies
Market Cap:$132.58M

AtriCure, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 50.00% and Analysts' Rating of 1.50. The short interest was 3.45% as of 08/02/2012. AtriCure, Inc., a medical device company, engages in developing, manufacturing, and selling cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue in the United States and internationally. Its product lines for cardiac tissue ablation includes AtriCure's synergy ablation system and related radio-frequency ablation devices, such as isolator bipolar radio-frequency ablation clamps for open-heart and minimally invasive procedures; ablation and sensing units, a compact power generator that delivers bipolar radio-frequency (RF) energy; AtriCure switch box to provide the technology needed for the dual pulsing electrodes, and to connect and toggle between multiple RF devices; and isolator multifunctional pens that are disposable RF devices enabling surgeons to toggle back and forth between temporary pacing, sensing, and stimulation and ablation. The company also offers cryoablation system, which consists of various reusable and disposable devices, including the Frigitronics CCS-200 product line for cardiac ablation; cryoIce, a disposable cryoablation device; and cryoICE BOX, a cryo generator, as well as AtriClip system, which is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart.

2) NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)

Market Cap:$636.65M

NPS Pharmaceuticals, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 80.00% and Analysts' Rating of 1.30. The short interest was 7.53% as of 08/02/2012. NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company's primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders.

3) MAP Pharmaceuticals, Inc. (NASDAQ:MAPP)

Industry:Drug Manufacturers - Other
Market Cap:$407.78M

MAP Pharmaceuticals, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 49.00% and Analysts' Rating of 1.40. The short interest was 16.68% as of 08/02/2012. MAP Pharmaceuticals, Inc., a development stage company, focuses on the enhancement of the therapeutic benefits and commercial attractiveness of proven drugs in the field of neurology through its formulation and inhalation technologies. The company's lead product candidate includes LEVADEX, an orally inhaled version of dihydroergotamine mesylate (DHE) that has completed Phase III clinical trials for the acute treatment of migraine in adults. Its proprietary technologies consist of particle creation and formulation technologies, which can be applied to small or large molecules, including peptides and proteins; and aerosol delivery platforms, such as TEMPO inhaler, a pressurized metered dose inhaler (MDI) that dispenses drug automatically when the patient inhales.

4) Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Industry:Drug Manufacturers - Major
Market Cap:$127.43M

Keryx Biopharmaceuticals Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 30.00% and Analysts' Rating of 1.40. The short interest was 14.65% as of 08/02/2012. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Zerenex is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis.

5) Emergent BioSolutions, Inc. (NYSE:EBS)

Market Cap:$509.86M

Emergent BioSolutions, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 32.00% and Analysts' Rating of 1.30. The short interest was 4.32% as of 08/02/2012. Emergent BioSolutions, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of vaccines and therapeutics for use in defense and commercial markets to healthcare providers and purchasers in the United States and internationally. It markets BioThrax, a vaccine for the prevention of anthrax disease. The company's products also include BioThrax PEP, which is in Phase III clinical trials; PreviThrax ands Anthrivig that are in Phase II clinical trials; and NuThrax and Thravixa, which are in Phase I clinical trials for the treatment of Anthrax.

*Company profiles were sourced from Google Finance and Yahoo Finance. Financial data was sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.